Kaia Back Pain App Published Study Impressive

Medical Device News Magazine reports in the largest independent randomized controlled trial (RCT) of its type, a multimodal app-based therapy program for patients with non-specific low back pain has outperformed standard-of-care treatment across all medical outcomes. Results of the study, published in the Journal of Pain Research, show that patients using Kaia, the back pain management app developed by leading digital therapeutics company Kaia Health, reduced pain levels, anxiety, depression, stress, and improved wellbeing and body functionality significantly more compared to standard-of-care treatments (which can be whatever the physicians typically prescribe, e.g. pain killers, surgeries, physical therapy).

“This large-scale study demonstrates the significant benefits for people managing low back pain when using Kaia to deliver a multimodal treatment through a digital device, such as a smartphone,” says Thomas R. Toelle, M.D., Ph.D., Head of the Pain Center of the Technical University Munich, Germany. “These results add to the growing body of medical evidence that supports the use of digital multimodal treatments for chronic conditions, such as back pain.”

Low back pain is one of the leading causes of global disability, with an enormous cost for healthcare systems worldwide. 1,2 According to a 2018 report on the impact of musculoskeletal pain on employers, chronic pain, including back pain, accounts for 188.7 million lost work days, and $62.4 billion in lost productivity cost.3

Available on the AppStore and Google Play, Kaia is an app-based, multimodal digital therapy program for back pain, which focuses on Physical therapy, Relaxation exercises, and Medical education.

“COVID is changing the way that health care is delivered and driving a meaningful increase in demand for multimodal virtual therapy solutions. We’re focused on the highest level of clinical rigor to protect the health of patients, and significantly improve their chronic pain; remotely, effectively and at scale,” says Kaia Founder and President, Konstantin Mehl. “Companies looking to integrate digital back pain therapy into their health plan for employees can trust that the Kaia treatment is medically sound.”

Kaia Health recently announced news of a $26 million Series B funding, which included new investment from top healthcare VC Optum Ventures and world number one ranked Golfer Rory McIlroy.

About the Cluster-Randomised Controlled Trial: In the study, 1,245 patients with low back pain were randomized either to the intervention group (n=933) or the control group (n=312). The intervention group (IG) used the Kaia app with physicians applying a treatment algorithm. In the control group (CG), physicians prescribed standard-of-care treatments. Pain rating on the numeric rating scale was the primary outcome measure. Psychological measures (anxiety, depression, stress), functional ability, as well as physical and mental wellbeing, served as secondary outcomes.

Patients were assessed at the beginning of the treatment and at 3-month follow-ups. The IG group showed a significantly stronger pain reduction compared to the CG after three months (IG: M=-33.3% vs CG: M=-14.3%). The IG group was also superior in secondary outcomes. Furthermore, high-risk patients who received a teleconsultation showed a larger decrease in pain intensity (-43.5%) than CG patients (-14.3%).


References

1.     Dalys, G. B. D. & Collaborators, H. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1260–1344 (2017).

2.     Maher, C., Underwood, M. & Buchbinder, R. Non-specific low back pain. Lancet 389, 736–747 (2017).

3.     The impact of musculoskeletal pain on employers (2018)

4.     Priebe, Janosch A. et al. Digital treatment of back pain versus standard of care: The cluster-randomized controlled trial, Rise-uP (2020) https://www.dovepress.com/digital-treatment-of-back-pain-versus-standard-of-care-the-cluster-ran-peer-reviewed-fulltext-article-JPR#

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”